Antigen and Molecular Testing
Molecular or antigen testing for SARS-CoV-2 is medically necessary when ALL of the following criteria are met:
ALL of the following
Testing is primarily intended for individualized diagnosis of COVID-19 or for pre-procedural testing; claims for pre-procedural testing should use the correct diagnosis code, such as Z208.22, to support proper claims payment.
Testing is ordered by a licensed or otherwise authorized health care provider acting within the scope of the provider's license or authorization.
The test is FDA approved or has an Emergency Use Authorization (EUA).
Testing is performed by a CLIA-accredited laboratory or is CLIA-waived as indicated in the test instructions for use.
The Plan may request the applicable CLIA certification or waiver and the manufacturer and name of the test performed.
Antibody Testing
Antibody testing may be medically necessary when ALL applicable criteria are met:
ALL of the following
The molecular or antigen testing criteria above are met.
Results will be used to diagnose a condition related to COVID-19 infection, such as multisystem inflammatory syndrome in children (MIS-C).
The antibody test is not used as the sole basis for diagnosis.
The FDA believes serological tests should not be used as the sole basis for diagnosis.
Recurrent Testing
High-frequency testing may be subject to medical-necessity review.
ALL of the following
Testing is performed in accordance with the applicable molecular, antigen, or antibody testing criteria.
Medical records demonstrate that the testing was medically appropriate and performed in accordance with current accepted standards of medical practice.
Records may be requested, particularly for multiple tests per day for a single member.
Non-Covered, Non-Diagnostic Testing
Antigen and antibody in vitro testing for SARS-CoV-2 is NOT medically necessary when the applicable diagnostic criteria are not met, including testing for any of the following purposes:
ONE of the following
A purpose not primarily intended to diagnose an individual with COVID-19.
Public health surveillance testing, including epidemiologic research purposes; research-related testing billed with CPT 87913 is not reimbursed. Employment or school purposes, including return-to-work or return-to-school programs, general workplace or school safety screening, work- or school-related travel, sports participation, pre-employment verification, routine physicals, or insurance purposes.
General screening, including travel, social requirements, community tracking, or determining the need for personal protective equipment.
Diagnostic and Antibody Testing
Diagnostic and serological testing is covered when ALL applicable statutory, authorization, and medical-necessity requirements are met:
ALL of the following
The test is an in vitro diagnostic test for detection of SARS-CoV-2 or diagnosis of COVID-19, or is a serological test otherwise meeting the applicable statutory requirements.
The test is approved, cleared, or authorized under applicable provisions of the Federal Food, Drug, and Cosmetic Act, including section 510(k), 513, 515, or 564; is developed under an applicable emergency-use authorization pathway; is developed in and authorized by a state that has notified the HHS Secretary of its intent to review COVID-19 diagnostic tests; or is otherwise determined appropriate by the HHS Secretary in guidance.
An attending health care provider makes an individualized clinical assessment that testing is medically appropriate for the individual based on current accepted standards of medical practice.
The provider is licensed or otherwise authorized under applicable law, acts within the scope of the provider's license or authorization, and is responsible for providing care to the patient.
At-Home Antigen Testing
At-home COVID-19 testing is covered only when ALL applicable requirements are met:
ALL of the following
The test is ordered by an attending health care provider who has determined that it is medically appropriate for the individual based on current accepted standards of medical practice.
The test otherwise meets the applicable statutory criteria under section 6001(a)(1) of the FFCRA, as amended by section 3201 of the CARES Act.
The test is an authorized, cleared, or approved diagnostic test, including a test involving self-collection of a specimen at home.
Recurrent Diagnostic Testing
When diagnostic-testing requirements are satisfied, recurrent testing has no stated numerical limit.
ALL of the following
Each test is diagnostic and medically appropriate for the individual, as determined by an attending health care provider in accordance with current accepted standards of medical practice.
Providers consider applicable CDC guidance and guidance issued by state, tribal, territorial, and local health departments or professional societies when determining whether recurrent diagnostic testing is appropriate.
Surveillance and Workplace Testing
Outside the applicable FFCRA coverage scope
Testing to screen for general workplace health and safety, including employee return-to-work programs.
Public health surveillance for SARS-CoV-2, including epidemiologic research purposes.
Any purpose not primarily intended for individualized diagnosis or treatment of COVID-19 or another health condition.
As of July 1, 2023, over-the-counter COVID-19 testing is not covered.
This policy does not address panel testing for SARS-CoV-2 infection and COVID-19 diagnosis. See the Respiratory Viral Panels medical policies for applicable criteria: Respiratory Viral Panels, MP256 (Company), and Respiratory Viral Panels, MP255 (Medicare).
Over-the-counter COVID-19 testing is not covered as of July 1, 2023, including at-home over-the-counter tests notwithstanding the earlier federal requirement for coverage of eight tests per covered individual per month beginning January 15, 2022.
Workplace, return-to-work, school, surveillance, travel, social, community-tracking, and other testing purposes not primarily intended for individualized diagnosis or treatment are outside the applicable FFCRA coverage scope and are not covered as diagnostic testing under this policy.
Research-related testing billed with CPT 87913 is not reimbursed.
COVID-19 research-related testing billed with CPT 87913 is not reimbursed.
Antigen and antibody testing is not medically necessary when the applicable individualized diagnostic, provider-order, authorization, laboratory, or other medical-necessity criteria are not met.
FDA approval, clearance, or authorization alone does not establish medical necessity or serve as a basis for coverage. FDA Emergency Use Authorization allowed certain COVID-19 tests without traditional FDA approval; the FDA maintains listings of authorized serological tests for informational purposes.